Abbott Laboratories (ABT) EV/Sales Ratio: 4.07x
Is Abbott Laboratories’s EV/Sales ratio high or low?
Abbott Laboratories's EV/Sales ratio of 4.07x is 18% below its 5-year average of 4.98x, near the low end of its 5-year range (3.74x–6.20x).
As of Thursday, June 11, 2026. 17.56% below its 12-month average of 4.94x.
ABT EV/Sales Ratio Chart
ABT Average EV/Sales Ratio Chart
ABT Current vs Average EV/Sales Ratio Chart
ABT EV/Sales Ratio Metrics
EV/SALES RATIO
4.07x
EV/SALES RATIO AVG TTM
4.94x
EV/SALES RATIO AVG 3Y
5.00x
EV/SALES RATIO AVG 5Y
4.98x
EV/SALES RATIO AVG 10Y
4.93x
EV/SALES RATIO AVG 15Y
4.09x
EV/SALES RATIO AVG 20Y
3.52x
CURRENT VS TTM AVG
-17.56%
CURRENT VS 3Y AVG
-18.65%
CURRENT VS 5Y AVG
-18.29%
CURRENT VS 10Y AVG
-17.37%
CURRENT VS 15Y AVG
-0.47%
CURRENT VS 20Y AVG
+15.75%
ABT Competitors' EV/Sales Ratio
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Abbott Laboratories (ABT) | $155.75B | 4.07x | 4.94x | 5.00x | 4.98x |
| Gilead Sciences, Inc. (GILD) | $156.35B | 5.61x | 6.02x | 4.98x | 4.64x |
| Pfizer Inc. (PFE) | $149.61B | 3.37x | 3.30x | 3.43x | 3.63x |
| Intuitive Surgical, Inc. (ISRG) | $144.79B | 13.82x | 18.43x | 19.52x | 18.69x |
| Thermo Fisher Scientific Inc. (TMO) | $176.21B | 4.80x | 5.13x | 5.38x | 5.61x |
| CVS Health Corporation (CVS) | $126.70B | 0.48x | 0.44x | 0.43x | 0.51x |
| Danaher Corporation (DHR) | $126.39B | 5.79x | 6.63x | 7.16x | 7.00x |
| Amgen Inc. (AMGN) | $188.37B | 6.15x | 6.19x | 6.53x | 6.38x |
| Bristol-Myers Squibb Company (BMY) | $116.13B | 3.12x | 2.99x | 3.12x | 3.47x |
| Vertex Pharmaceuticals Incorporated (VRTX) | $110.59B | 8.91x | 9.43x | 10.00x | 9.07x |
Understanding EV/Sales
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
- It works for unprofitable companies where P/E doesn't apply
- Revenue is harder to manipulate than earnings
- It supports comparisons across companies at different profitability stages
- It is frequently used for software and other revenue-growth-focused companies
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
Abbott Laboratories EV/Sales Ratio Formula & Definition
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Abbott Laboratories EV/Sales Ratio FAQ
- What is the EV/Sales ratio for Abbott Laboratories (ABT)?
- The EV/Sales ratio for ABT stock is 4.07x.
- Is Abbott Laboratories's EV/Sales ratio high or low?
- Abbott Laboratories's EV/Sales ratio of 4.07x is 18% below its 5-year average of 4.98x, near the low end of its 5-year range (3.74x–6.20x).
- What is the TTM average EV/Sales ratio for Abbott Laboratories (ABT)?
- The TTM average EV/Sales ratio for ABT stock is 4.94x.
- What is the 3Y average EV/Sales ratio for Abbott Laboratories (ABT)?
- The 3Y average EV/Sales ratio for ABT stock is 5.00x.
- What is the 5Y average EV/Sales ratio for Abbott Laboratories (ABT)?
- The 5Y average EV/Sales ratio for ABT stock is 4.98x.
- What is the 10Y average EV/Sales ratio for Abbott Laboratories (ABT)?
- The 10Y average EV/Sales ratio for ABT stock is 4.93x.
- What is the 15Y average EV/Sales ratio for Abbott Laboratories (ABT)?
- The 15Y average EV/Sales ratio for ABT stock is 4.09x.
- What is the 20Y average EV/Sales ratio for Abbott Laboratories (ABT)?
- The 20Y average EV/Sales ratio for ABT stock is 3.52x.
Abbott Laboratories EV/Sales Ratio History
| DATE | EV/SALES RATIO |
|---|---|
| 2026-06-11 | 4.07x |
| 2026-06-10 | 4.06x |
| 2026-06-09 | 4.14x |
| 2026-06-08 | 4.11x |
| 2026-06-05 | 4.13x |
| 2026-06-04 | 4.12x |
| 2026-06-03 | 3.97x |
| 2026-06-02 | 3.97x |
| 2026-06-01 | 4.00x |
| 2026-05-29 | 3.92x |
| 2026-05-28 | 3.94x |
| 2026-05-27 | 3.92x |
| 2026-05-26 | 3.96x |
| 2026-05-22 | 3.99x |
| 2026-05-21 | 4.00x |
| 2026-05-20 | 4.02x |
| 2026-05-19 | 4.04x |
| 2026-05-18 | 4.01x |
| 2026-05-15 | 3.87x |
| 2026-05-14 | 3.89x |
| 2026-05-13 | 3.85x |
| 2026-05-12 | 3.87x |
| 2026-05-11 | 3.80x |
| 2026-05-08 | 3.87x |
| 2026-05-07 | 3.97x |
| 2026-05-06 | 3.94x |
| 2026-05-05 | 3.98x |
| 2026-05-04 | 3.99x |
| 2026-05-01 | 4.07x |
| 2026-04-30 | 4.12x |
| 2026-04-29 | 4.14x |
| 2026-04-28 | 3.85x |
| 2026-04-27 | 3.80x |
| 2026-04-24 | 3.74x |
| 2026-04-23 | 3.79x |
| 2026-04-22 | 3.76x |
| 2026-04-21 | 3.80x |
| 2026-04-20 | 3.93x |
| 2026-04-17 | 3.96x |
| 2026-04-16 | 3.91x |
| 2026-04-15 | 4.15x |
| 2026-04-14 | 4.13x |
| 2026-04-13 | 4.12x |
| 2026-04-10 | 4.10x |
| 2026-04-09 | 4.20x |
| 2026-04-08 | 4.23x |
| 2026-04-07 | 4.16x |
| 2026-04-06 | 4.18x |
| 2026-04-02 | 4.20x |
| 2026-04-01 | 4.18x |
| 2026-03-31 | 4.19x |
| 2026-03-30 | 4.16x |
| 2026-03-27 | 4.25x |
| 2026-03-26 | 4.27x |
| 2026-03-25 | 4.28x |
| 2026-03-24 | 4.25x |
| 2026-03-23 | 4.28x |
| 2026-03-20 | 4.30x |
| 2026-03-19 | 4.37x |
| 2026-03-18 | 4.42x |
| 2026-03-17 | 4.51x |
| 2026-03-16 | 4.48x |
| 2026-03-13 | 4.41x |
| 2026-03-12 | 4.41x |
| 2026-03-11 | 4.49x |
| 2026-03-10 | 4.50x |
| 2026-03-09 | 4.59x |
| 2026-03-06 | 4.47x |
| 2026-03-05 | 4.52x |
| 2026-03-04 | 4.61x |
| 2026-03-03 | 4.63x |
| 2026-03-02 | 4.65x |
| 2026-02-27 | 4.73x |
| 2026-02-26 | 4.73x |
| 2026-02-25 | 4.67x |
| 2026-02-24 | 4.66x |
| 2026-02-23 | 4.69x |
| 2026-02-20 | 4.57x |
| 2026-02-19 | 4.60x |
| 2026-02-18 | 4.64x |
| 2026-02-17 | 4.60x |
| 2026-02-13 | 4.62x |
| 2026-02-12 | 4.57x |
| 2026-02-11 | 4.66x |
| 2026-02-10 | 4.60x |
| 2026-02-09 | 4.55x |
| 2026-02-06 | 4.55x |
| 2026-02-05 | 4.48x |
| 2026-02-04 | 4.44x |
| 2026-02-03 | 4.47x |
| 2026-02-02 | 4.49x |
| 2026-01-30 | 4.48x |
| 2026-01-29 | 4.36x |
| 2026-01-28 | 4.35x |
| 2026-01-27 | 4.44x |
| 2026-01-26 | 4.46x |
| 2026-01-23 | 4.41x |
| 2026-01-22 | 4.46x |
| 2026-01-21 | 4.94x |
| 2026-01-20 | 4.96x |
| 2026-01-16 | 4.98x |
| 2026-01-15 | 5.05x |
| 2026-01-14 | 5.11x |
| 2026-01-13 | 5.08x |
| 2026-01-12 | 5.10x |
| 2026-01-09 | 5.15x |
| 2026-01-08 | 5.16x |
| 2026-01-07 | 5.19x |
| 2026-01-06 | 5.22x |
| 2026-01-05 | 5.17x |
| 2026-01-02 | 5.08x |
| 2025-12-31 | 5.12x |
| 2025-12-30 | 5.14x |
| 2025-12-29 | 5.09x |
| 2025-12-26 | 5.10x |
| 2025-12-24 | 5.10x |
| 2025-12-23 | 5.09x |
| 2025-12-22 | 5.12x |
| 2025-12-19 | 5.13x |
| 2025-12-18 | 5.12x |
| 2025-12-17 | 5.18x |
| 2025-12-16 | 5.18x |
| 2025-12-15 | 5.25x |
| 2025-12-12 | 5.13x |
| 2025-12-11 | 5.04x |
| 2025-12-10 | 5.01x |
| 2025-12-09 | 4.96x |
| 2025-12-08 | 4.99x |
| 2025-12-05 | 5.11x |
| 2025-12-04 | 5.13x |
| 2025-12-03 | 5.12x |
| 2025-12-02 | 5.16x |
| 2025-12-01 | 5.23x |
| 2025-11-28 | 5.27x |
| 2025-11-26 | 5.25x |
| 2025-11-25 | 5.23x |
| 2025-11-24 | 5.20x |
| 2025-11-21 | 5.23x |
| 2025-11-20 | 5.07x |
| 2025-11-19 | 5.16x |
| 2025-11-18 | 5.31x |
| 2025-11-17 | 5.31x |
| 2025-11-14 | 5.33x |
| 2025-11-13 | 5.28x |
| 2025-11-12 | 5.26x |
| 2025-11-11 | 5.19x |
| 2025-11-10 | 5.15x |
| 2025-11-07 | 5.16x |
| 2025-11-06 | 5.11x |
| 2025-11-05 | 5.09x |
| 2025-11-04 | 5.14x |
| 2025-11-03 | 5.06x |
| 2025-10-31 | 5.06x |
| 2025-10-30 | 5.10x |
| 2025-10-29 | 5.09x |
| 2025-10-28 | 5.29x |
| 2025-10-27 | 5.32x |
| 2025-10-24 | 5.30x |
| 2025-10-23 | 5.28x |
| 2025-10-22 | 5.35x |
| 2025-10-21 | 5.33x |
| 2025-10-20 | 5.41x |
| 2025-10-17 | 5.37x |
| 2025-10-16 | 5.33x |
| 2025-10-15 | 5.41x |
| 2025-10-14 | 5.56x |
| 2025-10-13 | 5.49x |
| 2025-10-10 | 5.54x |
| 2025-10-09 | 5.57x |
| 2025-10-08 | 5.60x |
| 2025-10-07 | 5.55x |
| 2025-10-06 | 5.58x |
| 2025-10-03 | 5.62x |
| 2025-10-02 | 5.55x |
| 2025-10-01 | 5.57x |
| 2025-09-30 | 5.59x |
| 2025-09-29 | 5.56x |
| 2025-09-26 | 5.57x |
| 2025-09-25 | 5.57x |
| 2025-09-24 | 5.59x |
| 2025-09-23 | 5.67x |
| 2025-09-22 | 5.70x |
| 2025-09-19 | 5.68x |
| 2025-09-18 | 5.62x |
| 2025-09-17 | 5.60x |
| 2025-09-16 | 5.54x |
| 2025-09-15 | 5.48x |
| 2025-09-12 | 5.58x |
| 2025-09-11 | 5.54x |
| 2025-09-10 | 5.40x |
| 2025-09-09 | 5.51x |
| 2025-09-08 | 5.52x |
| 2025-09-05 | 5.55x |
| 2025-09-04 | 5.54x |
| 2025-09-03 | 5.52x |
| 2025-09-02 | 5.49x |
| 2025-08-29 | 5.54x |
| 2025-08-28 | 5.49x |
| 2025-08-27 | 5.49x |
| 2025-08-26 | 5.50x |
| 2025-08-25 | 5.51x |
| 2025-08-22 | 5.54x |
| 2025-08-21 | 5.51x |
| 2025-08-20 | 5.53x |
| 2025-08-19 | 5.48x |
| 2025-08-18 | 5.44x |
| 2025-08-15 | 5.50x |
| 2025-08-14 | 5.40x |
| 2025-08-13 | 5.41x |
| 2025-08-12 | 5.47x |
| 2025-08-11 | 5.49x |
| 2025-08-08 | 5.60x |
| 2025-08-07 | 5.51x |
| 2025-08-06 | 5.47x |
| 2025-08-05 | 5.46x |
| 2025-08-04 | 5.43x |
| 2025-08-01 | 5.32x |
| 2025-07-31 | 5.28x |
| 2025-07-30 | 5.37x |
| 2025-07-29 | 5.44x |
| 2025-07-28 | 5.37x |
| 2025-07-25 | 5.38x |
| 2025-07-24 | 5.34x |
| 2025-07-23 | 5.35x |
| 2025-07-22 | 5.35x |
| 2025-07-21 | 5.29x |
| 2025-07-18 | 5.26x |
| 2025-07-17 | 5.13x |
| 2025-07-16 | 5.59x |
| 2025-07-15 | 5.58x |
| 2025-07-14 | 5.61x |
| 2025-07-11 | 5.61x |
| 2025-07-10 | 5.67x |
| 2025-07-09 | 5.66x |
| 2025-07-08 | 5.66x |
| 2025-07-07 | 5.68x |
| 2025-07-03 | 5.71x |
| 2025-07-02 | 5.69x |
| 2025-07-01 | 5.78x |
| 2025-06-30 | 5.77x |
| 2025-06-27 | 5.70x |
| 2025-06-26 | 5.67x |
| 2025-06-25 | 5.83x |
| 2025-06-24 | 5.86x |
| 2025-06-23 | 5.66x |
| 2025-06-20 | 5.65x |
| 2025-06-18 | 5.62x |
| 2025-06-17 | 5.62x |
| 2025-06-16 | 5.69x |
| 2025-06-13 | 5.75x |
| 2025-06-12 | 5.79x |
| 2025-06-11 | 5.74x |
| 2025-06-10 | 5.69x |
| 2025-06-09 | 5.66x |
| 2025-06-06 | 5.67x |
| 2025-06-05 | 5.69x |
| 2025-06-04 | 5.64x |
| 2025-06-03 | 5.68x |
| 2025-06-02 | 5.67x |
| 2025-05-30 | 5.67x |
Showing the most recent 260 of 5,032 data points. The chart above shows the full history.
Related Metrics
About Abbott Laboratories
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Robert Ford